Report cover image

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Aug 30, 2022
Length 69 Pages
SKU # GMD17396377

Description

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022'; Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O2−) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns.

The report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022' outlays comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal and Genetic Disorders which include indications Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Parkinson's Disease, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Wilson Disease.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
  • The report reviews Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

69 Pages
Introduction
Global Markets Direct Report Coverage
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) – Overview
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) – Companies Involved in Therapeutics Development
AL-S Pharma AG
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Apic Bio Inc
Avrion Therapeutics AG
Biogen Inc
Collaborative Medicinal Development LLC
Novartis Gene Therapies
ProMIS Neurosciences Inc
ResQ Biotech
Thera Neuropharma Inc
Voyager Therapeutics Inc
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) – Drug Profiles
ALN-SOD – Drug Profile
AP-101 – Drug Profile
APB-102 – Drug Profile
AVR-001 – Drug Profile
AVXS-301 – Drug Profile
Cu(II)ATSM – Drug Profile
NU-9 – Drug Profile
Recombinant Peptides to Inhibit Superoxide Dismutase (SOD1) for Amyotrophic Lateral Sclerosis – Drug Profile
RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis – Drug Profile
Small Molecules to Inhibit SOD1 for Amyotrophic Lateral Sclerosis – Drug Profile
SOD1 – Drug Profile
TDI-186 – Drug Profile
THN-1 – Drug Profile
tiomolibdate choline – Drug Profile
tofersen sodium – Drug Profile
VYSOD-101 – Drug Profile
VYSOD-102 – Drug Profile
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) – Dormant Products
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) – Product Development Milestones
Featured News & Press Releases
Jul 27, 2022: FDA grants priority review for Biogen’s tofersen to treat ALS
Jul 26, 2022: Ionis announces that FDA accepts New Drug Application and grants priority review of tofersen for a rare, genetic form of ALS
Jun 23, 2022: ALXN1840 shows rapid and sustained improvement in copper mobilization from tissues, potentially closing treatment gaps for Wilson Disease community
Jun 03, 2022: Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
Jun 03, 2022: New 12-month tofersen data presented at ENCALS meeting show clinically meaningful benefit in people with SOD1-ALS
Nov 18, 2021: Neurimmune and TVM Capital Life Science announce the initiation of AL-S Pharma's phase 2 Study of AP-101 for the treatment of ALS
Oct 18, 2021: Biogen’s tofersen fails to meet primary goal in Phase III ALS trial
Oct 17, 2021: Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
Oct 14, 2021: Topline results from Tofersen phase 3 study and its open label extension in SOD1-ALS to be presented at the American Neurological Association Annual Meeting
Aug 27, 2021: Alexion’s drug meets primary goal in Phase III Wilson disease trial
Jul 28, 2021: Apic Bio receives FDA fast track designation for APB-102 for the treatment of patients with SOD1 ALS
Apr 21, 2021: Apic Bio announces FDA clearance of IND application for lead gene therapy candidate APB-102 for the treatment of SOD1 ALS
Feb 23, 2021: ALS neuron damage reversed with new compound
Jul 23, 2020: Investigational drug for genetic form of ALS showing early promise, trial indicates
Jul 13, 2020: New treatment for motor neurone disease shows promise in early trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development by Stage of Development, 2022
Table 2: Number of Products under Development by Therapy Areas, 2022
Table 3: Number of Products under Development by Indication, 2022
Table 4: Number of Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Number of Products under Investigation by Universities/Institutes, 2022
Table 8: Products under Investigation by Universities/Institutes, 2022
Table 9: Number of Products by Stage and Mechanism of Actions, 2022
Table 10: Number of Products by Stage and Route of Administration, 2022
Table 11: Number of Products by Stage and Molecule Type, 2022
Table 12: Pipeline by AL-S Pharma AG, 2022
Table 13: Pipeline by Alexion Pharmaceuticals Inc, 2022
Table 14: Pipeline by Alnylam Pharmaceuticals Inc, 2022
Table 15: Pipeline by Apic Bio Inc, 2022
Table 16: Pipeline by Avrion Therapeutics AG, 2022
Table 17: Pipeline by Biogen Inc, 2022
Table 18: Pipeline by Collaborative Medicinal Development LLC, 2022
Table 19: Pipeline by Novartis Gene Therapies, 2022
Table 20: Pipeline by ProMIS Neurosciences Inc, 2022
Table 21: Pipeline by ResQ Biotech, 2022
Table 22: Pipeline by Thera Neuropharma Inc, 2022
Table 23: Pipeline by Voyager Therapeutics Inc, 2022
Table 24: Dormant Projects, 2022
List of Figures
Figure 1: Number of Products under Development by Stage of Development, 2022
Figure 2: Number of Products under Development by Therapy Areas, 2022
Figure 3: Number of Products under Development by Top 10 Indications, 2022
Figure 4: Number of Products by Mechanism of Actions, 2022
Figure 5: Number of Products by Stage and Mechanism of Actions, 2022
Figure 6: Number of Products by Routes of Administration, 2022
Figure 7: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 8: Number of Products by Molecule Types, 2022
Figure 9: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us